Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint
Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc GILD.O reports quarterly results this month. Its remdesivir, the first…